Related Experiment Video
Updated: Nov 1, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
Statin associated lower cancer risk and related mortality in patients with heart failure
Qing-Wen Ren1,2, Si-Yeung Yu1,2, Tiew-Hwa Katherine Teng3,4,5
1Cardiology Division, Department of Medicine, The University of Hong Kong Shen Zhen Hospital, No. 1 Haiyuan 1st Rd, Futian district, Shenzhen city, Guangdong province, 518009, China.
European Heart Journal
|June 22, 2021
Summary
Statin use in heart failure (HF) patients is linked to a reduced risk of developing cancer and dying from it. This protective effect increases with longer statin therapy duration.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Patients with heart failure (HF) face a higher risk of developing cancer.
- Limited data exists on statin use's impact on cancer risk and mortality in HF patients.
Purpose of the Study:
- To investigate the association between statin use and the risk of incident cancer and cancer-related mortality in patients with heart failure.
- To determine if the duration of statin use influences these risks.
Main Methods:
- Utilized a territory-wide clinical information registry (2003-2015) with 87,102 HF patients.
- Employed inverse probability of treatment weighting and competing risk regression with Cox proportional-hazard models.
- Analyzed cancer incidence and cancer-related mortality based on statin use and duration.
Main Results:
- Statin use was associated with a 16% lower risk of cancer incidence (SHR=0.84; 95% CI, 0.80-0.89).
- The cancer risk reduction was duration-dependent, with significant benefits observed for users of ≥4 years.
- Ten-year cancer-related mortality was lower in statin users (3.8%) vs. non-users (5.2%) (SHR=0.74; 95% CI, 0.67-0.81).
Conclusions:
- Statin use in HF patients is significantly associated with a lower risk of incident cancer.
- The association between statin use and reduced cancer risk and mortality in HF patients appears to be duration-dependent.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
01:26Atherosclerosis III: Management
87
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
87
01:30Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
01:22Heart Failure Drugs: β-Blockers
538
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
01:26Angina IV: Management
87
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
87
01:26Coronary Artery Disease IV: Preventive Measures
431
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
431